8/19/2010

The FDA granted orphan-drug designation to ImmunoGen's
lorvotuzumab mertasine as a treatment for small-cell lung cancer. The treatment previously obtained orphan-drug status for Merkel cell carcinoma in the U.S. and Europe.

Related Summaries